Source comparison
Ipamorelin Benefits: Research Comparison Table
Before selecting ipamorelin, researchers often compare it to other growth hormone secretagogues and direct GH administration. The table below compares receptor selectivity, hormonal side effects, half-life, and typical research applications. Ipamorelin Selecti
This comparison does not assign a generated winner or score.
- Before selecting ipamorelin, researchers often compare it to other growth hormone secretagogues and direct GH administration. The table below compares receptor selectivity, hormonal side effects, half-life, and typical research applications.
- Ipamorelin
- Selective GHS-R1a agonist (ghrelin mimetic)
- None. No ACTH or prolactin activation
- 2 hours
- 0.1–0.3 µg/kg SC
- Metabolic studies, sleep research, tissue repair models
- Gold standard for selective GH release without confounding stress hormones. Ideal when isolating pure GH/IGF-1 axis effects
- GHRP-6
- Non-selective ghrelin receptor agonist
- Significant. 40–60% cortisol increase, 25–35% prolactin increase
- 2–3 hours
- 1–2 µg/kg SC
- Appetite signaling research, ghrelin pathway studies
- Robust GH release but hormonal cross-reactivity limits metabolic and anabolic interpretation. Use only when broader ghrelin effects are the study target
- CJC-1295 (no DAC)
- GHRH analog. Stimulates endogenous GHRH receptors
- Minimal
- 30 minutes (short-acting)
- 100–200 µg SC
- Synergistic GH protocols, circadian rhythm studies
- Amplifies endogenous GH pulses without blunting feedback loops. Pairs well with ipamorelin for maximal physiological GH response
- Recombinant Human GH
- Direct exogenous GH administration
- Variable. Suppresses endogenous pulsatility
- 20–30 minutes IV; longer SC
- 0.1–0.3 mg/day SC
- Dose-controlled anabolic research, receptor saturation studies
- Bypasses secretagogue pathways entirely. Allows precise GH dosing but eliminates natural pulsatility and can suppress endogenous secretion over time
- MK-677 (Ibutamoren)
- Oral GHS-R agonist (long-acting ghrelin mimetic)
- Moderate. Some cortisol elevation, appetite stimulation
- 24 hours
- 10–25 mg orally
- Chronic oral dosing studies, cachexia models
- Convenient oral administration and long half-life useful for sustained studies, but less selective than ipamorelin. Appetite and insulin changes complicate metabolic endpoints